Arcturus Therapeutics Holdings Inc.
Close on Oct 19, 2026
- Market cap
- $296.17M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $3.00M | $-0.84 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | After market close | $7.20M | $-1.03 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | $17.20M | $-0.49 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | $28.30M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | $29.40M | $-0.52 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | After market close | $22.80M | $-1.11 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $41.70M | $-0.26 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | After market close | – | – | – |
Press releases
Announcements Arcturus Therapeutics filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Arcturus Therapeutics Announces Interim OTC
Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
Results of operations · EX-99.1 to Form 8-K
Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Meiji Seika Pharma Launches Two-Dose Vial of
Regulation FD disclosure · EX-99.1 to Form 8-K
Meiji Seika Pharma Receives Approval in
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
Results of operations · EX-99.1 to Form 8-K
Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
Results of operations · EX-99.1 to Form 8-K
Arcturus Therapeutics Announces Third Quarter
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
Results of operations · EX-99.1 to Form 8-K
Arcturus Therapeutics Appoints Moncef Slaoui,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
Results of operations · EX-99.1 to Form 8-K
Positive Results of Phase III Study of Bivalent
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
Results of operations · EX-99.1 to Form 8-K
Arcturus Therapeutics Announces Third Quarter
Results of operations · EX-99.1 to Form 8-K
Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic
Material agreement · Other events · EX-99.1 to Form 8-K
Arcturus Therapeutics Joint Venture mRNA Manufacturing
Material agreement · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
Results of operations · Other events · EX-99.1 to Form 8-K
Name of Company: Meiji Holdings Co., Ltd.
Regulation FD disclosure · EX-99.1 to Form 8-K
Arcturus Therapeutics Announces First Quarter
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED APRIL 28, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Arcturus Therapeutics Announces Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Appoints John Markels, Ph.D. to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcturus Therapeutics Announces Third Quarter
Results of operations · EX-99.1 to Form 8-K
Arcturus Therapeutics Announces Second Quarter
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
Results of operations · EX-99.1 to Form 8-K
Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
Material agreement · Agreement terminated · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K